Lynozyfic received accelerated approval for relapsed multiple myeloma, showing a 70% response rate but with notable side effects, including cytokine release syndrome and neurologic toxicity. Zegfrovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback